---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-179837"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:57:07.563797+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Enliven reports Q2 net loss $25.3M; positive ELVN-001 Phase 1 data with 47% MMR rate

## Summary
- Phase 1 trial of ELVN-001 in CML: 47% cumulative MMR rate; 32% achieved MMR by 24 weeks, favorable safety.
- Cash, cash equivalents and marketable securities $490.5M as of June 30, 2025; cash runway into first half of 2029.
- Net loss of $25.3M for Q2 2025 vs $20.0M in Q2 2024; R&D expenses $21.5M, G&A $7.1M.
- Company plans to initiate Phase 3 pivotal trial of ELVN-001 in 2026.
- Recent public offering generated $230M gross proceeds, strengthening balance sheet.

## SEC filing metadata
- accession: 0001193125-25-179837
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312525179837/0001193125-25-179837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312525179837/elvn-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-179837
- JSON: https://secwatch.observer/filing/0001193125-25-179837.json
- Plain text: https://secwatch.observer/filing/0001193125-25-179837.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.